MNOV: Phase 2 Trial of MN-001 in NAFLD Patients with Type 2 Diabetes and Hypertriglyceridemia Underway…
By David Bautz, PhD
NASDAQ:MNOV
READ THE FULL MNOV RESEARCH REPORT
MediciNova Reached Agreement to Participate in Grant-Funded Clinical Trial to Evaluate MN-166 (ibudilast) for the Treatment of Long COVID
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that it plans to participate in RECLAIM (Recovering from COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial), a grant-funded, multi-
Recap Of Tuesday’s Biotech Catalysts – End of The Day Summary
European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg…
MNOV: Positive Results for MN-166 (Ibudilast) in Patients at Risk of Acute Respiratory Distress Syndrome…
By David Bautz, PhD
NASDAQ:MNOV
READ THE FULL MNOV RESEARCH REPORT
Zacks Small-Cap Research Issues Note On MediciNova, Set $27 Valuation
https://s27.q4cdn.com/906368049/files/News/2022/Zacks_SCR_Research_06132022_MNOV_Bautz.pdf.pdf
83 Biggest Movers From Yesterday
Gainers
Symbotic Inc. (NASDAQ: SYM) shares surged 120.6% to settle at $20.07 on Wednesday. Symbotic reported the completion of its business combination with SVF Investment Corp. to become a publicly traded company.
The Daily Biotech Pulse: FDA Adcomm Backing For Novavax’s COVID-19 Shot, New Data On Moderna’s Omicron Vaccine, DBV Tech’s Encouraging Peanut Allergy Trial Data
Here's a roundup of top developments in the biotech space over the last 24 hours:
MediciNova Posts Promising Data From COVID-19 Treatment Candidate
MediciNova Inc (NASDAQ:MNOV) says the Phase 2 trial of MN-166 (ibudilast) in hospitalized COVID-19 patients demonstrated significant improvements compared to placebo…
MediciNova Announces Top-Line Results From Phase 2 Clinical Trial Of MN-166 In Hospitalized COVID-19 Patients At Risk For Acute Respiratory Distress Syndrome; Trial Achieved Statistical Significance For One Of Co-Primary Endpoints
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced positive top-line results from